Open AccessHidden Horror Challenges for Oral Mucormycosis with COVID 19 Patients Case Series Original Study
Author(s) -
Rawaa Y. AlRawee,
Ali Mohammad Saeed,
A Al-Omari,
Bashar Abdul-Ghani Tawfeeq,
Saud Salim Saeed
Publication year - 2021
Publication title -
trends in internal medicine
Language(s) - English
Resource type - Journals
ISSN - 2771-5906
DOI - 10.33425/2771-5906.1006
Subject(s) - mucormycosis , diabetes mellitus , medicine , concomitant , covid-19 , mann–whitney u test , mortality rate , gastroenterology , surgery , disease , infectious disease (medical specialty) , endocrinology
Authors: Rawaa Y. Al-Rawee, Ali Mohammad Saeed, Ahmed khaldoon Tariq Alomari, Bashar Abdul-Ghani Tawfeeq, Saud Salim Saeed. Purpose: Explore the early identification significance of mucormycosis in Covid 19 patients and highlighting the role of MDT cooperation in reducing mortality and morbidity rate. Material and Method: Forty-three patients are included in this study as mucormycosis infection with diabetes mellitus (MID) divided in 2 groups: group 1: 15 patients recorded to have mucormycosis infection with diabetesmellitus only (MID), group 2: 28 patients recorded to have previous Covid attack added to mucormycosis infection with diabetes mellitus (CMID). Result: Mann-Whitney Test and Wilcoxon W test are used for detection of significant differences between 2 groups where z value considers less than 0.5 to be significant. Severity and stages confirm high significant difference between MID and CMID (0.042, 0.000) while prognosis confirm no significant differences (0.521). Conclusion: Diabetic patients are more prone to have viral and bacterial infections make them need special care. COVID-19 with the immune dysregulation is concomitant with a significant prevalence of fungal infections as secondary attacks; early diagnosis and management can help in reduce subsequently mortality and morbidity.